Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets SmartVest high-frequency chest wall oscillation airway-clearance systems for home-care and institutional patients. This report covers the three months ended September 30, 2015, the first quarter of fiscal 2016, compared with the three months ended September 30, 2014. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 FY2016 | Q1 FY2015 | Change |
|---|---|---|---|
| Net revenue | $5.001 million | $4.771 million | 4.8% increase |
| Gross profit | $3.859 million | $3.295 million | 17.1% increase |
| Gross margin | 77.2% | 69.1% | Up 8.1 percentage points |
| Operating income | $585,000 | $398,000 | 47.0% increase |
| Net income | $341,000 | $378,000 | 9.7% decrease |
| Diluted EPS | $0.04 | $0.05 | Decrease |
| Operating cash flow | $311,000 | $955,000 | Decrease of $643,000 |
Home-care revenue was $4.486 million, up 12.3%, supported by improved reimbursement operations, new third-party payer contracts, faster approval cycles, higher average selling prices and improved referral-to-approval rates. Institutional revenue increased 5.1% to $395,000. International revenue declined 69.9% to $120,000, primarily because the prior-year period benefited from distributors accelerating purchases before RoHS 2 compliance changes.
SG&A increased 14.6% to $3.233 million, reflecting higher sales and support headcount, compensation, equity compensation, professional fees and travel costs. Research and development expense decreased 44.0% to $42,000 as major SmartVest SQL manufacturing-cost-reduction projects were substantially completed. Interest expense was approximately $20,000 in both periods.
Income tax expense was $224,000 in Q1 FY2016, producing a 39.4% effective tax rate, compared with no tax expense in the prior-year quarter. The company continued to maintain a full valuation allowance against its U.S. deferred tax assets.
Liquidity, Debt and Balance Sheet
- Cash increased to $3.783 million at September 30, 2015 from $3.598 million at June 30, 2015.
- Working capital was approximately $10.8 million. Total current assets were $12.897 million versus current liabilities of $2.132 million.
- The company generated $311,000 of operating cash flow, used $115,000 in investing activities and made $12,000 of debt principal payments, resulting in a $185,000 net increase in cash.
- The $2.5 million revolving credit facility had no outstanding balance, and the full $2.5 million was eligible for borrowing at September 30, 2015.
- The Venture Bank term loan had approximately $1.231 million outstanding, bearing interest at 5.00%, with a final payment of approximately $1.090 million due December 18, 2018.
- The company was in compliance with its debt covenants, including a minimum tangible net worth requirement of $10.125 million.
- On November 5, 2015, after quarter-end, the revolving credit facility was renewed through December 18, 2016. Upon effectiveness, the interest rate changes to the prime rate with no floor.
Material Changes, Outlook and Risks
- Profit declined despite stronger revenue, gross margin and operating income because the company recorded $224,000 of income tax expense versus none in the prior-year period.
- Management expects research and development spending to return to approximately 2.0% of net revenue over the next 12 months as engineering resources focus on product enhancements and market opportunities.
- Management believes existing working capital, operating cash flow and available borrowing capacity will provide adequate liquidity for the next year, but additional debt may be required for unforeseen capital needs or weaker operating performance.
- Management believes that continued profitability may provide sufficient positive evidence within the next 12 months to release a significant portion, potentially all, of the deferred-tax-asset valuation allowance. The timing and amount remain uncertain.
- Key risks include reimbursement and healthcare-policy changes, competition, international-market and regulatory risks, intellectual-property protection, regulatory approvals, credit-facility availability, covenant compliance and general economic conditions.
- The company provides a lifetime warranty on U.S. home-care products and a three-year warranty on institutional and non-U.S. sales. The warranty reserve was $630,000 at September 30, 2015.
- The company abandoned approximately $8,000 of outdated patents during the quarter and recorded the amount in SG&A. No material off-balance-sheet arrangements or undisclosed material litigation were reported.
Investor Verification Items
- Verify whether home-care revenue growth and reimbursement-process improvements persist after the quarter.
- Monitor the sustainability of the 77.2% gross margin and the effect of higher SG&A spending on operating leverage.
- Assess operating cash conversion, particularly inventory, prepaid-asset and accrued-liability movements.
- Confirm continued compliance with the Venture Bank covenants and the terms and availability of the renewed credit facility.
- Evaluate the likelihood and timing of any deferred-tax-valuation-allowance release and its effect on future tax expense.
- Track international sales volatility, distributor purchasing patterns and regulatory compliance in foreign markets.